Trial Profile
A Multi-centre, Multi-national Open Study in Patients With Hepatic Cirrhosis to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cholyl lysyl fluorescein (Primary)
- Indications Liver cirrhosis
- Focus Pharmacokinetics
- Sponsors Norgine
- 21 May 2014 New trial record